<DOC>
	<DOCNO>NCT02387983</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety oral posaconazole tablet Chinese participant high risk invasive fungal infection . Neutropenic participant undergo chemotherapy acute myelogenous leukemia myelodysplastic syndrome enrol study .</brief_summary>
	<brief_title>Pharmacokinetics Safety Oral Posaconazole ( MK-5592 ) Tablets Chinese Participants High Risk Invasive Fungal Infections ( MK-5592-117 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Chinese participant Female reproductive potential serum hCG level consistent nongravid state agree use 2 acceptable method birth control throughout study Body Mass Index ( BMI ) &gt; =15 &lt; =30 kg/m^2 Anticipated document prolong neutropenia likely last least 7 day due : ) standard intensive chemotherapy , anthracyclinebased accept regimen ( exclude investigational agent ) new diagnosis acute myelogenous leukemia ( AML ) ; b ) chemotherapy AML first relapse ; c ) therapy myelodysplastic syndrome transformation AML diagnose secondary AML ( therapy relate , antecedent hematological disorder ) chronic myelogenous leukemia blast crisis Free clinically significant disease primary hematologic disease would interfere administration study medication study evaluation Pregnant , intend become pregnant study , nurse Mentally legally incapacitate , significant emotional problem , clinically significant psychiatric disorder last 5 year Received systemic antifungal therapy ( oral , intravenous , inhale ) within 30 day study enrollment reason antifungal prophylaxis Known suspected invasive systemic fungal infection Taken posaconazole within 10 day prior study enrollment Major surgery , donate lose 1 unit blood , participate another investigational study within 4 week prior study Type 1 hypersensitivity idiosyncratic reaction azole agent Significant multiple severe allergy , anaphylactic reaction significant intolerability drug food Moderate severe liver dysfunction Chronic active hepatitis , cirrhosis , Hepatocellular Carcinoma ( HCC ) , hepatic disease cause virus Previous electrocardiogram prolong QTc interval Prior enrollment study posaconazole study within 90 day study entry Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 prior induction chemotherapy underlying disease Known suspect Gilbert 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>